<DOC>
	<DOCNO>NCT00360464</DOCNO>
	<brief_summary>To evaluate clinical efficacy safety patient Acute Bronchitis Secondary Infection Chronic Respiratory Diseases receive dose 2 g azithromycin SR formulation .</brief_summary>
	<brief_title>A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<criteria>Patients diagnose mild moderate severity classification infection Japanese Society Chemotherapy guideline evaluation method new antibacterial drug ( establish 1997 ) . Severe underlying disease ; patient drug clinical evaluation difficult confounding disease .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>